Plain-English translation of NCT06920043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medicine called alfa to see if it can help people who have cirrhosis (scarring of the liver) caused by metabolic dysfunction-associated steatohepatitis, or MASH—a condition where fat builds up in the liver. Researchers want to learn whether the medication is safe, well-tolerated, and whether it actually works to improve liver function. About 42 people will participate, with some receiving the medication at different doses and others receiving a placebo (a dummy treatment).
Currently, there are very limited treatment options for people with advanced fatty liver disease that has progressed to cirrhosis. This medication is being tested to see if it can offer a new way to help slow or reverse liver damage in patients who have this serious condition.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of either the test medication or a placebo once every four weeks. The study will monitor you closely with blood tests and check-ups to make sure the treatment is safe and to see if it's helping your liver. The exact length of the study and number of visits will be explained to you in detail before you decide to join.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States